MedTrace Logo

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

NCT01910610 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 464

Last updated 2024-03-12

No results posted yet for this study

Summary

STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.

Conditions

  • Colorectal Cancer Metastatic

Interventions

BIOLOGICAL

FOLFIRI-cetuximab

BIOLOGICAL

mFOLFOX6-bevacizumab

BIOLOGICAL

OPTIMOX-bevacizumab

BIOLOGICAL

irinotecan-based chemo + bevacizumab

BIOLOGICAL

Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)

BIOLOGICAL

XELOX + bevacizumab

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    lead OTHER

Principal Investigators

  • Benoist Chibaudel, MD · Institut Hospitalier Franco-Britannique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-30
Primary Completion
2023-07-13
Completion
2024-12-31

Countries

  • France
  • Ireland
  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01910610 on ClinicalTrials.gov